Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983 ...
The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...